Please assess the completion status of the following clinical trial:

Trial Title: Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 60 or older (M/F)~2. Evidence of mild parkinsonian signs (incl. slow gait (\< 1m/s))~Exclusion Criteria:~1. Presence of clinically significant degenerative joint disease and/or neuropathy interfering with proper assessment of the motor UPDRS exam.~2. Presence of significant dementia.~3. Evidence of a large vessel stroke in a clinically relevant area (cerebral cortex, basal ganglia, thalamus) or mass lesion on structural brain imaging (MRI).~4. Participants in whom magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant.~5. Severe claustrophobia precluding neuroimaging procedures.~6. Hypersensitivity to the carbidopa, levodopa, and tablet components.~7. Any other medical history determined by investigators to preclude safe participation.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).